Four small off-white ceramic cups in a row on sage linen, the first one filled with water
Four small off-white ceramic cups in a row on sage linen, the first one filled with water

Your first month on a GLP-1: what to expect week by week

A rough map, because no two first months look the same

November 19, 2026 · 5 min read
Updated November 18, 2026
Text it

Checkin shares general health information from FDA labels and published studies. It isn't medical advice, so check with your prescriber about your medicine. Questions about this? Text Checkin, it's free.

The short answer: The first month on a GLP-1 usually starts with a low starter dose, and the labels say most stomach side effects, like nausea and diarrhea, happen while doses are stepping up. Sip fluids, keep meals small, and talk to your prescriber about how it's going; they decide each next step.

Starting Ozempic, Wegovy, Mounjaro or Zepbound comes with a lot of questions. This is a walk through the first four weeks: what the labels say, what you may notice, and what's worth telling your prescriber.

1.Week 1: what is a starter dose?

Each of these medicines begins at a starting dose. The Ozempic, Wegovy and Zepbound labels list a starting dose for the first four weeks (sections 2.2, 2.2 and 2.1). The Mounjaro label also lists a starting dose, and says the dose goes up from there if more blood sugar control is needed (section 2.1).

Why start low? The labels give the reason in one line:

“Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions”
What the label saysOzempic prescribing information, section 2.2

"Gastrointestinal adverse reactions" means stomach and gut side effects. Stepping up slowly is meant to make those less likely. Your prescriber decides your dose and every step after it.

The weekly shots are simple to time. The Ozempic label says to take it "once weekly, on the same day each week, at any time of the day, with or without meals" (section 2.1). The Wegovy label says the same about its shot.

2.What happens to the shot after you take it?

These shots are subcutaneous. That means the medicine goes into the fatty layer just under the skin, not into a muscle or a vein. The labels list three places: the abdomen, the thigh or the upper arm (Ozempic section 2.1).

From that layer, the medicine moves slowly into your blood. For semaglutide (Ozempic and Wegovy), the label says the highest level is reached "1 to 3 days post dose" (Ozempic section 12.3). For tirzepatide (Mounjaro and Zepbound), the middle time to the highest level is 24 hours, with a range of 8 to 72 hours (Zepbound section 12.3).

Then it stays around. In your blood there is a common protein called albumin, and the medicine is built to hold on to it. The Ozempic label says this albumin binding "results in decreased renal clearance and protection from metabolic degradation" (section 12.1). In plain words: your kidneys clear it slowly and your body breaks it down slowly.

That is why one shot lasts a week. Semaglutide has a half-life of about 1 week (Ozempic section 12.3). Half-life is the time it takes for the amount in your body to drop by half. Tirzepatide has a part that "enables albumin binding and prolongs the half-life" (Zepbound section 12.1), and its half-life is about 5 to 6 days (Zepbound section 12.3).

3.Which side effects are most common at the start?

The Ozempic Medication Guide lists the most common ones: "nausea, vomiting, diarrhea, stomach (abdominal) pain, and constipation."

“The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation.”
What the label saysOzempic prescribing information, section 6.1

Dose escalation is the stepping-up period. The Mounjaro and Zepbound labels say the same thing about timing, and add that these side effects "decreased over time" (section 6.1).

4.Week 2: why do I feel full sooner?

You may notice that you feel full sooner, or stay full longer. One reason is in the labels: "Semaglutide delays gastric emptying" (Wegovy section 12.2). Gastric emptying is how fast food leaves your stomach. When that slows down, food sits in the stomach longer.

For tirzepatide, the label adds a detail about timing: "The delay is largest after the first dose and this effect diminishes over time" (Zepbound section 12.2).

The brain is part of it too. The Wegovy label says the GLP-1 receptor "is present in several areas of the brain involved in appetite regulation" (section 12.1). A receptor is a spot on a cell that the medicine attaches to.

5.Why do fluids matter in the first weeks?

“Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration.”
What the label saysOzempic Medication Guide

The label for prescribers points to the same weeks. It tells them to check kidney function in people with side effects that could cause fluid loss, "especially during dosage initiation and escalation" (Ozempic section 5.6). That's the start and the step-ups.

So if your stomach is upset, steady sips matter. The labels don't give an amount. Your care team can tell you what's right for you.

6.Week 3: what helps with eating?

This part is not from the labels. A 2025 joint advisory from four US nutrition and obesity medicine societies, written for clinicians, discusses a few things that may help:

  • For nausea: small meals every few hours, with enough fluids.
  • For constipation: fluids and fiber from food.
  • Through the month: enough protein.

The advisory is guidance for clinicians, so ask your clinician or a dietitian what targets make sense for you.

7.Week 4: what happens next?

The next step comes from your prescriber. The Wegovy and Zepbound labels tell prescribers to "consider treatment response and tolerability" when choosing the long-term dose (Wegovy section 2.2, Zepbound section 2.1). Tolerability means how well you're handling the medicine.

If a step is hard to handle, the labels give prescribers room to slow down. The Wegovy label says to consider delaying the next step when a dose isn't tolerated (section 2.2).

8.When should I call my doctor?

The Ozempic Medication Guide names a few things that shouldn't wait:

  • Severe pain in your stomach area that will not go away, with or without vomiting. This can be a sign of pancreatitis, an inflamed pancreas. The guide says to stop using the medicine and call your healthcare provider right away.
  • Nausea, vomiting or diarrhea that does not go away. Tell your healthcare provider right away.
  • Pain in your upper stomach, or yellowing of your skin or eyes. These can be signs of gallbladder problems. Tell your healthcare provider right away.

How Checkin helps in your first weeks

Checkin is a free AI companion for GLP-1s that you text. For this part of life on a GLP-1, it does three things:

  • Text “took my shot”

    It's logged, so you can see your weeks add up.

  • It checks in two days after your shot

    A quick text to see how you're feeling, timed to your shot day.

  • Ask anything

    Plain answers from the FDA label, with a picture when it helps.

Questions people ask

Is nausea normal in the first month?

Nausea is one of the most common side effects, and the labels say most of it happens while doses are stepping up. Tell your provider if it doesn't go away.

When will I move up a dose?

Your prescriber decides when and whether to step up, based on how you respond and how well you tolerate it.

Can I take my shot at any time of day?

Yes. Weekly shots are taken on the same day each week, at any time of day, with or without meals.

How much water should I drink?

The labels don't give a number; they say drinking fluids helps lower your chance of dehydration. Ask your care team what's right for you.

Sources

  1. DailyMed: Ozempic (semaglutide) prescribing information, sections 2.1, 2.2, 5.6, 6.1, 12.1 and 12.3, and Medication Guide
  2. DailyMed: Wegovy (semaglutide) prescribing information, sections 2.1, 2.2, 12.1 and 12.2
  3. DailyMed: Mounjaro (tirzepatide) prescribing information, sections 2.1 and 6.1
  4. DailyMed: Zepbound (tirzepatide) prescribing information, sections 2.1, 6.1, 12.1, 12.2 and 12.3
  5. Nutritional priorities to support GLP-1 therapy for obesity: joint advisory from ACLM, ASN, OMA and TOS (Am J Clin Nutr 2025;122(1):344-367)

Published November 19, 2026. General information, not medical, legal or insurance advice. Check with your prescriber, pharmacist or plan.

The Checkin team writes these guides from FDA labels and published studies, and lists a source for every claim. Read more about Checkin, or text it free.

Related guides